drugset / Trial / NCT07640555
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
Phase 0
Recruiting
13 enrolled
MODAG GmbH
Institute for Neurodegenerative Disorders · collabXingImaging, LLC · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \[¹⁸F\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study. Each participant will receive a single intravenous injection of \[¹⁸F\]MODAG-009, followed by PET imaging using the investigational United Imaging NeuroEXPLORER (NX) camera.
Timeline
- Start
- 2026-05-13
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [¹⁸F]MODAG-009 | Diagnostic / imaging agent | 296 mbq | Intravenous |